Pricing

Cheapest Tirzepatide at a Maintenance Dose (Not the Starting Dose)

Almost every ranking of cheap tirzepatide compares advertised starting prices. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance do

Why every “cheapest” list is answering the wrong question

Search for the cheapest compounded tirzepatide and you will get a list ordered by advertised entry price: $99, $125, $129, $133, $146. Those are real numbers and they are almost all starting-dose numbers.

The tirzepatide label directs 2.5 mg once weekly for four weeks, then an increase to 5 mg, then increases in 2.5 mg increments no sooner than every four weeks, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages and states plainly that 2.5 mg is not approved as a maintenance dosage.

So a ranking built on the entry price ranks providers on a figure nobody pays after month one. It is the single most consequential error in this category, and it is nearly universal.

The dose tax

Where a programme charges more as your dose rises, the difference between the advertised price and what you actually pay is a dose tax. It is not hidden — it is in the terms — but it is rarely in the headline, and it compounds every month for as long as you stay on treatment.

Two structures exist:

Tiered. The price rises with the dose. Brand Zepbound direct from LillyDirect runs $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg upward. Several compounded programmes work the same way, with reported ladders reaching $299 or $499 at maintenance doses.

Flat. One price across every covered dose. Your bill at 15 mg is your bill at 2.5 mg.

The comparison that matters

Three columns, not one: what you pay at the starting dose, what you pay at 10 mg, and what twelve months actually costs. A programme advertising $99 that reaches $299 at maintenance costs more across a year than one advertising $186 that never moves.

We publish all three wherever we hold the data, and we mark the cells we do not hold rather than leaving them blank. Several providers do not publish their escalation ladder at all — which is itself the answer to whether their advertised figure describes treatment.

Where NexLife sits, stated plainly

NexLife is not the cheapest starting price in this market. Programmes advertise entry rates from around $99, and NexLife (opens nexlife.us in a new tab)'s compounded tirzepatide is reported at $215 month-to-month, falling to $195 on three months, $190 on six and $186 on twelve.

What it does is hold that price across every covered dose. There is no escalation, no membership fee, and the $186 twelve-month figure is the one we captured directly from its own plan pages on 11 July 2026 — the only provider price on this site that carries our own dated capture.

So the honest positioning is narrow and defensible: if you expect to titrate to a maintenance dose and stay there, a flat-rate programme is likely cheaper across a year than a lower-advertised one that escalates. If you genuinely maintain at a low dose, the cheaper entry price may win. Both can be true, and which applies to you is a clinical question about your dose, not a marketing question about a headline.

Four questions that settle it for any provider

1. What do I pay at 10 mg? Not at the starting dose. This one question resolves most of the confusion in this market.
2. Does the price change as the dose rises, and by how much at each step? Get the ladder in writing.
3. Is a membership required to receive medication? Memberships in our dataset run $19.99 to $149 a month, and at the top of that range can equal the medication.
4. Is the advertised rate an introductory price? Eleven programmes in our dataset advertise a first-month rate. All are excluded from every ranking here.

The route that beats all of this

Insurance. Where a commercial plan covers a brand GLP-1 the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until 31 December 2027. Both are below every compounded programme in our dataset at any dose.

Establishing whether you qualify takes one phone call and is worth more than every comparison on this page.

Questions readers actually ask

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.